Giuseppe Gullo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Giuseppe Gullo has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Lorenza Rimassa
Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Italy
2 shared publications A. Bertuzzi
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano (Milano), Italy
1 shared publicationA. Santoro
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano (Milano), Italy
1 shared publication- Annemarie Larkin
National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
1 shared publication Armando Santoro
Istituto Clinico Humanitas IRCCS
1 shared publication- Armando Santoro
Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, Rozzano (Milan), Italy
1 shared publication
Latest Publications
- Open Access
- 24 June 2009
- Published by Springer Nature in BMC Urology
- Vol. 9 (1) , 6
Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma
Background: Renal cell carcinoma patients respond poorly to conventional chemotherapy, this unresponsiveness may be attributable to multidrug resistance (MDR). The mechanisms of MDR in renal cancer are not fully understood and the specific contribution of ABC transporter proteins which have been implicated in the chemoresistance of various cancers has not been fully defined in this disease.Methods: In this retrospective study the expression of two of these transporter efflux pumps, namely MDR-1 P-gp (ABCB1) and MRP-1 (ABCC1) were studied by immunohistochemistry in archival material from 95 renal cell carcinoma patients.Results: In the first study investigating MDR-1 P-gpandMRP-1 protein expression patterns in renal cell carcinoma patients, high levels of expression of both efflux pumps are observed with 100% of tumours studied showing MDR-1 P-gpandMRP-1 positivity.Conclusion: Although these findings do not prove a causal role, the high frequency of tumours expressing these efflux pumps suggests that they may be important contributors to the chemoresistance of this tumour type.
- 24 June 2009
- Published by Springer Nature in BMC Urology
- Vol. 9 (1) , 6
Open AccessExpression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma
Background: Renal cell carcinoma patients respond poorly to conventional chemotherapy, this unresponsiveness may be attributable to multidrug resistance (MDR). The mechanisms of MDR in renal cancer are not fully understood and the specific contribution of ABC transporter proteins which have been implicated in the chemoresistance of various cancers has not been fully defined in this disease.Methods: In this retrospective study the expression of two of these transporter efflux pumps, namely MDR-1 P-gp (ABCB1) and MRP-1 (ABCC1) were studied by immunohistochemistry in archival material from 95 renal cell carcinoma patients.Results: In the first study investigating MDR-1 P-gpandMRP-1 protein expression patterns in renal cell carcinoma patients, high levels of expression of both efflux pumps are observed with 100% of tumours studied showing MDR-1 P-gpandMRP-1 positivity.Conclusion: Although these findings do not prove a causal role, the high frequency of tumours expressing these efflux pumps suggests that they may be important contributors to the chemoresistance of this tumour type.
- Open Access
- 29 July 2008
- Published by Springer Nature in Investigational New Drugs
- Vol. 27 (2) , 179-183
Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer
To explore the clinical significance of the level of HER2/neu gene amplification in a homogenous cohort of 33 patients with HER2-positive metastatic breast cancer (MBC) and available tumor samples treated with a trastuzumab-based regimen, we retrospectively performed dual-color fluorescence in-situ hybridization test and correlated them for each patient with time-to-progression (TTP) and overall survival (OS). We obtained values of HER2/chromosome 17 centromere (CEP17) ratio ranging from 2.5 to 21 (median 7.2). At the Cox model there is indication that patients whose tumors have high-level HER2/CEP17 ratio have shorter TTP and OS than those with lower ratio, when treated with a trastuzumab-based regimen. Correlations do not reach the limits of statistical significance but no formal sample size calculation was performed due to the explorative nature of the study. If confirmed in larger cohorts of patients, HER2/CEP17 ratio could represent a reliable and economical predictor of response to trastuzumab-based therapy in MBC.
- 29 July 2008
- Published by Springer Nature in Investigational New Drugs
- Vol. 27 (2) , 179-183
Open AccessLevel of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer
To explore the clinical significance of the level of HER2/neu gene amplification in a homogenous cohort of 33 patients with HER2-positive metastatic breast cancer (MBC) and available tumor samples treated with a trastuzumab-based regimen, we retrospectively performed dual-color fluorescence in-situ hybridization test and correlated them for each patient with time-to-progression (TTP) and overall survival (OS). We obtained values of HER2/chromosome 17 centromere (CEP17) ratio ranging from 2.5 to 21 (median 7.2). At the Cox model there is indication that patients whose tumors have high-level HER2/CEP17 ratio have shorter TTP and OS than those with lower ratio, when treated with a trastuzumab-based regimen. Correlations do not reach the limits of statistical significance but no formal sample size calculation was performed due to the explorative nature of the study. If confirmed in larger cohorts of patients, HER2/CEP17 ratio could represent a reliable and economical predictor of response to trastuzumab-based therapy in MBC.
- 11 May 2007
- Published by Springer Nature in Investigational New Drugs
- Vol. 25 (5) , 479-485
The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study
Intra-arterial chemotherapy in patients with liver metastases from colorectal cancer has some limitations such as hepatic toxicity and extra-hepatic progression. With the aim of overcoming these limitations, a phase II trial was designed to assess the efficacy and tolerability of a hybrid chemotherapy regimen with systemic infusion of oxaliplatin and folinic acid associated with intra-arterial 5-fluorouracil. Thirty-nine patients with colorectal liver metastases were recruited. The median age was 59 years, 30 patients (77%) had synchronous metastases, and half of the patients were chemo-naive. A total of 313 chemotherapy cycles were administered (median number 8). Treatment was well tolerated and hepatic toxicity negligible. Out of 34 evaluable patients an ORR of 41%. was observed. Eight patients (21%) underwent radical liver surgery. The median time to progression (TTP) was 10 months (range 2–63) and the median overall survival (OS) 21 months (range 6–63). Extra-hepatic progression was observed in six patients. Our results suggest that this regimen is active even if technical complications are frequent. Our aim to reduce hepatic toxicity and extra-hepatic progression was reached.
- 11 May 2007
- Published by Springer Nature in Investigational New Drugs
- Vol. 25 (5) , 479-485
The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study
Intra-arterial chemotherapy in patients with liver metastases from colorectal cancer has some limitations such as hepatic toxicity and extra-hepatic progression. With the aim of overcoming these limitations, a phase II trial was designed to assess the efficacy and tolerability of a hybrid chemotherapy regimen with systemic infusion of oxaliplatin and folinic acid associated with intra-arterial 5-fluorouracil. Thirty-nine patients with colorectal liver metastases were recruited. The median age was 59 years, 30 patients (77%) had synchronous metastases, and half of the patients were chemo-naive. A total of 313 chemotherapy cycles were administered (median number 8). Treatment was well tolerated and hepatic toxicity negligible. Out of 34 evaluable patients an ORR of 41%. was observed. Eight patients (21%) underwent radical liver surgery. The median time to progression (TTP) was 10 months (range 2–63) and the median overall survival (OS) 21 months (range 6–63). Extra-hepatic progression was observed in six patients. Our results suggest that this regimen is active even if technical complications are frequent. Our aim to reduce hepatic toxicity and extra-hepatic progression was reached.
- Open Access
- 15 November 2005
- Published by Elsevier in Annals of Oncology
- Vol. 17 (4) , 719-720
High-dose chemotherapy as adjuvant treatment for high-risk primary breast cancer patients
In a study recently published in Annals of Oncology, Coombes et al. [1] reported the results of a prospective randomized trial comparing a short course of anthracycline-containing chemotherapy followed by high-dose chemotherapy with stem-cell support (HDCT) versus a conventional-dose anthracycline-containing chemotherapy (CDCT) as adjuvant treatment in breast cancer patients with four or more positive axillary lymph nodes. In their experience the authors did not observe any significant differences between HDCT and CDCT on disease-free and overall survival (OS) and they concluded that ‘patients should continue to receive conventional chemotherapy as adjuvant therapy for breast cancer’. However, this study does not seem to provide any clear information for the long-lasting controversy [2–5] on the role of HDCT in high-risk primary breast cancer (HRBC). Indeed, the trial was designed to investigate the benefits deriving from replacing three cycles of conventional anthracycline-containing chemotherapy with a single course of HDCT, and not to compare head-to-head HDCT versus CDCT in HRBC.
- 15 November 2005
- Published by Elsevier in Annals of Oncology
- Vol. 17 (4) , 719-720
Open AccessHigh-dose chemotherapy as adjuvant treatment for high-risk primary breast cancer patients
In a study recently published in Annals of Oncology, Coombes et al. [1] reported the results of a prospective randomized trial comparing a short course of anthracycline-containing chemotherapy followed by high-dose chemotherapy with stem-cell support (HDCT) versus a conventional-dose anthracycline-containing chemotherapy (CDCT) as adjuvant treatment in breast cancer patients with four or more positive axillary lymph nodes. In their experience the authors did not observe any significant differences between HDCT and CDCT on disease-free and overall survival (OS) and they concluded that ‘patients should continue to receive conventional chemotherapy as adjuvant therapy for breast cancer’. However, this study does not seem to provide any clear information for the long-lasting controversy [2–5] on the role of HDCT in high-risk primary breast cancer (HRBC). Indeed, the trial was designed to investigate the benefits deriving from replacing three cycles of conventional anthracycline-containing chemotherapy with a single course of HDCT, and not to compare head-to-head HDCT versus CDCT in HRBC.